March 2, 2022
Accure Therapeutics Licences Neuroprotective Drug Candidate to Ophthalmology Company Oculis
Oculis and Accure Therapeutics have announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a…